Dexcom reports Q3 2026 earnings beating estimates and raises full-year revenue outlook
Dexcom posted third‑quarter 2026 revenue of $1.344 billion, up 11% year‑over‑year, and non‑GAAP earnings per share of $0.73, surpassing Wall Street forecasts. Gross margin expanded to 65.1%, the highest since late‑2022. The company lifted its 2026 revenue guidance to $5.20‑$5.25 billion and announced a $1 billion share‑repurchase authorization. CEO Jacob Leach highlighted U.S. revenue growth of 14% and upcoming product launches.
Why it matters
The raised revenue guidance and $1 billion buyback indicate stronger cash generation and may support further shareholder returns. Investors should note the new full‑year revenue target of $5.20‑$5.25 billion.
Key facts
- 1Q3 2026 revenue was $1.344 billion, representing 11% organic growth year‑over‑year. investing.com
- 2Non‑GAAP EPS for the quarter was $0.73, a record for the company. investing.com
- 3Gross margin reached 65.1%, the highest level since late 2022. investing.com
- 4U.S. revenue was $969.8 million, up 14% year‑over‑year. investing.com
- 5Full‑year 2026 revenue guidance was raised to $5.20‑$5.25 billion. investing.com
- 6The company authorized a $1 billion share‑repurchase program. investing.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.